Edgewise: breaking away from dystrophin for muscular dystrophy

Edgewise emerges from stealth with $50M series B, dystrophin-independent muscle-stabilizing compounds

With a lead compound that staves off use-induced muscle damage, Edgewise thinks it can compete with dystrophin replacement therapies for muscular dystrophy.

Edgewise Therapeutics emerged from stealth this month with a $50 million series B round co-led by Novo Holdings A/S and U.S. Venture Partners and a portfolio of internally developed small molecule therapies for musculoskeletal indications including Duchenne and Becker muscular dystrophy.

Cure Duchenne Ventures, Deerfield Management, New Leaf Venture Partners and founding investor OrbiMed Advisors also participated

Read the full 788 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE